161 related articles for article (PubMed ID: 21189117)
1. Heterogeneity amongst 5-HT₃ receptor subunits: is this significant?
Yaakob N; Malone DT; Exintaris B; Irving HR
Curr Mol Med; 2011 Feb; 11(1):57-68. PubMed ID: 21189117
[TBL] [Abstract][Full Text] [Related]
2. 5-HT3 receptors.
Thompson AJ; Lummis SC
Curr Pharm Des; 2006; 12(28):3615-30. PubMed ID: 17073663
[TBL] [Abstract][Full Text] [Related]
3. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.
Machu TK
Pharmacol Ther; 2011 Jun; 130(3):338-47. PubMed ID: 21356241
[TBL] [Abstract][Full Text] [Related]
4. Visualising functional 5-HT
Abad IPL; Fam RL; Nguyen DT; Nowell CJ; Trinh PNH; Manallack DT; Freihat LA; Chakrabarti J; Jamil A; Exintaris B; Yaakob NS; Irving HR
Biomed Pharmacother; 2020 Dec; 132():110860. PubMed ID: 33059258
[TBL] [Abstract][Full Text] [Related]
5. Discriminating between 5-HT₃A and 5-HT₃AB receptors.
Thompson AJ; Lummis SC
Br J Pharmacol; 2013 Jun; 169(4):736-47. PubMed ID: 23489111
[TBL] [Abstract][Full Text] [Related]
6. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome.
Spiller RC
Curr Opin Pharmacol; 2011 Feb; 11(1):68-74. PubMed ID: 21398180
[TBL] [Abstract][Full Text] [Related]
7. 5-HT(3) receptors.
Lummis SC
J Biol Chem; 2012 Nov; 287(48):40239-45. PubMed ID: 23038271
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the novel human serotonin receptor subunits 5-HT3C,5-HT3D, and 5-HT3E.
Niesler B; Walstab J; Combrink S; Möller D; Kapeller J; Rietdorf J; Bönisch H; Göthert M; Rappold G; Brüss M
Mol Pharmacol; 2007 Jul; 72(1):8-17. PubMed ID: 17392525
[TBL] [Abstract][Full Text] [Related]
9. Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan.
Nakamura Y; Ishida Y; Yamada T; Kondo M; Shimada S
J Neurochem; 2013 Apr; 125(1):7-15. PubMed ID: 23305320
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
[TBL] [Abstract][Full Text] [Related]
11. Natural Negative Allosteric Modulators of 5-HT₃ Receptors.
Al Kury LT; Mahgoub M; Howarth FC; Oz M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30513973
[TBL] [Abstract][Full Text] [Related]
12. The C and E subunits of the serotonin 5-HT
Yaakob NS; Nguyen DT; Exintaris B; Irving HR
Biomed Pharmacother; 2018 Jan; 97():1701-1709. PubMed ID: 29793334
[TBL] [Abstract][Full Text] [Related]
13. The Human Serotonin Type 3 Receptor Gene (HTR3A-E) Allelic Variant Database.
Celli J; Rappold G; Niesler B
Hum Mutat; 2017 Feb; 38(2):137-147. PubMed ID: 27763704
[TBL] [Abstract][Full Text] [Related]
14. Importance of recognition loops B and D in the activation of human 5-HT₃ receptors by 5-HT and meta-chlorophenylbiguanide.
Michaelson SD; Paulsen IM; Kozuska JL; Martin IL; Dunn SM
Neuropharmacology; 2013 Oct; 73():398-403. PubMed ID: 23810831
[TBL] [Abstract][Full Text] [Related]
15. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
16. Emerging treatments in chemotherapy-induced nausea and vomiting.
Grunberg SM; Slusher B; Rugo HS
Clin Adv Hematol Oncol; 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18. PubMed ID: 23598819
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
Trigg ME; Higa GM
J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
[TBL] [Abstract][Full Text] [Related]
18. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
Schwartzberg LS; Jacobs P; Matsouka P; Azevedo W; Pinto A
Crit Rev Oncol Hematol; 2012 Jul; 83(1):59-70. PubMed ID: 22321726
[TBL] [Abstract][Full Text] [Related]
19. Naturally occurring variations in the human 5-HT3A gene profoundly impact 5-HT3 receptor function and expression.
Krzywkowski K; Jensen AA; Connolly CN; Bräuner-Osborne H
Pharmacogenet Genomics; 2007 Apr; 17(4):255-66. PubMed ID: 17496724
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting.
Rojas C; Slusher BS
Eur J Pharmacol; 2012 Jun; 684(1-3):1-7. PubMed ID: 22425650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
